ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GSK Gsk Plc

1,368.00
26.50 (1.98%)
03 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  26.50 1.98% 1,368.00 1,370.00 1,370.50 1,372.00 1,341.00 1,341.00 7,655,918 16:35:06
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1889 11.53 55.61B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,341.50p. Over the last year, Gsk shares have traded in a share price range of 1,282.50p to 1,820.00p.

Gsk currently has 4,145,087,815 shares in issue. The market capitalisation of Gsk is £55.61 billion. Gsk has a price to earnings ratio (PE ratio) of 11.53.

Gsk Share Discussion Threads

Showing 33451 to 33474 of 34075 messages
Chat Pages: Latest  1339  1338  1337  1336  1335  1334  1333  1332  1331  1330  1329  1328  Older
DateSubjectAuthorDiscuss
31/7/2024
07:40
Does anyone understand the fall? What is the rationale? Or is it better to simply accept that markets are irrational?
theoriginalwonderstuff
31/7/2024
07:35
Just hold - long term this is a bargain!
mj19
31/7/2024
07:29
I'll be adding my third and final tranche today for a long term hold in my ISA
dope007
31/7/2024
07:19
GSK can't catch a break! Raises guidance and still falls
mj19
31/7/2024
07:04
Lols ridiculous opening
dope007
31/7/2024
06:44
GSK, a pharmaceutical group, reported that 2Q core rose 13% on year at constant exchange rates to 43.4 pence. The company lifted its full-year core EPS growth guidance to 10% - 12% from 8% - 10% previously.
mj19
31/7/2024
06:36
Aye can't grumble at that .. just need the Zantac issue to clear up.
dplewis1
31/7/2024
06:28
Healthy numbers..

GSK delivers continued strong performance and upgrades 2024 guidance



Broad-based performance drives sales, core profit and core EPS growth:



Total Q2 2024 sales £7.9 billion +13% 



Vaccines sales +1%, +3% ex COVID. Shingrix £0.8 billion -4%



Specialty Medicines sales +22%. HIV sales  +13%. Oncology sales more than doubled at £0.4 billion 



General Medicines sales +12%. Trelegy £0.8 billion +41%



Total operating profit -22% and Total EPS -27% for Q2 2024 primarily reflected higher charges for CCL(1) remeasurements driven by improved longer term HIV prospects and foreign currency movements



Core operating profit +18% (with further positive impact of 3% ex COVID) and Core EPS +13% (with further positive impact of 4% ex COVID). This reflected continued leverage from strong sales and favourable product and regional mix, partly offset by continued increased investment in R&D and growth assets, and lower royalty income



Cash generated from operations in the quarter £1.7 billion with Free cash flow of £0.3 billion

(Financial Performance - Q2 2024 results unless otherwise stated, growth % and commentary at CER, ex COVID is excluding COVID-19 solutions

igoe104
30/7/2024
14:54
Does this mean we going down to £15 tomorrow
mj19
29/7/2024
14:32
LONDON and CAMBRIDGE, Mass., July 29, 2024 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.

This alliance brings together GSK's disease area expertise and development capability with Flagship's ecosystem of bioplatform companies, inclusive of its novel modalities and technologies, to make major advances in healthcare.

GSK and Flagship will initially fund up to $150 million upfront to support an exploration phase to identify the most promising concepts for further research and development with Flagship's bioplatform companies. From these explorations, the collaboration aims to identify a portfolio of up to 10 novel medicines and vaccines which will each be subject to an exclusive option by GSK for further clinical development.

tradermichael
29/7/2024
09:56
TraderMichael
Post 33172
"In April, Public Health England reported the results of a large study of COVID-19 transmission involving more than 365,000 households with a mix of vaccinated and unvaccinated members"


Interesting. Wasnt aware of this particular study.

So presumably you'll be getting your next covid jab then?

How many times have you had covid btw. I've had it at least twice as far as I am aware.

Zero Covid 19 vaccinations here. And I wont take the FLU vaccine either because they are going to make it a bivalent one(so you get Flu + Covid19 latest strain)


FYI I know of my several family members who have suffered "severe adverse events" post their 3rd Jab and will not take any more.

And as to excess deaths globally in countries with high vaccination rates.
Wonder that is all about.

Wil lwe ever get told the truth?

Decent news from GSK this morning has to be said.

geckotheglorious
29/7/2024
09:26
dplwise1 - that these claimants are settling like this indicates to me that the closer they get to a trial the weaker they feel their case is. Its likely that others will be deterred (and their ambulance-chasing lawyers) who are seeking mega-payouts rather than genuinely wanting to have their 'day in court' and are now prepared to take some money (and run).

There is no causal evidence that scientifically proves a direct link between Zantac itself and these unfortunate peoples' cancers.

tradermichael
29/7/2024
07:53
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approval of GSK’s respiratory syncytial virus (RSV) vaccine for the prevention of lower respiratory tract disease (LRTD) caused by RSV from adults aged 60 and above to include adults aged 50-59 years at increased risk for RSV disease.

Today’s positive opinion is the first time that an indication for adults aged 50-59 has been recommended by CHMP for a RSV vaccine, one of the final steps prior to the extension of the marketing authorisation by the European Commission. The European Commission’s final decision is expected by September 2024. Since June 2023, Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) has been approved in Europe for adults aged 60 and over for the prevention of RSV-LRTD.

tradermichael
29/7/2024
07:21
Zantac settlement with Ronald Kimbrow .. case now dismissed. Not a fan of this tbh I'm sure there are benefits to GSK but to the layman it just seems like as admission of guilt
dplewis1
27/7/2024
10:27
Nice to see a bounce off the 12 month TA support trend line at 1500, almost predictable.. :o), where to next..? the Zantac cases have not gone away, but oversold now down from the 1800 May high..
laurence llewelyn binliner
27/7/2024
09:29
In April, Public Health England reported the results of a large study of COVID-19 transmission involving more than 365,000 households with a mix of vaccinated and unvaccinated members.

It found immunisation with either the Pfizer or AstraZeneca vaccine reduced the chance of onward virus transmission by 40-60%. This means that if someone became infected after being vaccinated, they were only around half as likely to pass their infection on to others compared to infected people who weren’t vaccinated.

tradermichael
26/7/2024
15:51
TraderMichael

There was never any evidence that the Covid vaccines prevented transmission but they were foisted on everyone who couldnt afford to say NO regardless.

Chance these jabs delay Dementia minimal.

All part of the sales gimmick to encourage uptake.

And NO I wont be taking my Flu vaccine annually either.

geckotheglorious
26/7/2024
13:38
Interesting that the study was not performed by GSK. Its hard to see the pathway on how it would work, but the data set is already substantial. I doubt it will ever be recommended as a prevention but it may increase the uptake of shingrix. There is a little more here
dr biotech
26/7/2024
09:12
But there's evidence:

Researchers compared some 100,000 people who had a new (GSK) shingles jab to a similar group who had an older one. On average, those who had the new jab had an extra 164 days free from a diagnosis of dementia over six years. Further work is needed to prove the link, scientists say.

tradermichael
25/7/2024
21:39
>>Stock price chart suggests the yanks are the ones trading on the short side here

Yes, that's quite likely, especially considering the problems are mostly caused by US ambulance chasers.

kernelthread
25/7/2024
18:00
Shingles could delay Dementia.
Yeah righto.

You're the last person I'd expect to fall for that speculative gusto

geckotheglorious
25/7/2024
17:13
Would be a big market...
dr biotech
24/7/2024
07:54
Second tranche added. Very unloved this stock isn't it
dope007
23/7/2024
14:34
Good data. Stock price chart suggests the yanks are the ones trading on the short side here
dope007
Chat Pages: Latest  1339  1338  1337  1336  1335  1334  1333  1332  1331  1330  1329  1328  Older